Influence of pregnancy on outcomes of inflammatory bowel disease and treatment discontinuation

Table 1 Demographics, clinical characteristics, and laboratory data of the entire study group and subgroups according to inflammatory bowel disease type, median (interquartile range)/n (%)

	Study group (n = 57)	UC (n = 37)	CD (n = 20)
Age at onset of disease, years	22 (18-25.5)	23 (19.5-26)	20.5 (17.25-24.75)
Total disease duration, months	109 (72-154.23)	98.87 (65.37-151.88)	119.22 (94.53-197.03)
Smoking
None	50 (87.7)	34 (91.9)	16 (80)
Existing/current	7 (12.3)	3 (8.1)	4 (20)
BMI (kg/m2)	20.82 (18.59-23.44)	21.14 (17.44-24.1)	20.81 (19.4-22.77)
Family history of IBD	6 (10.5)	3 (8.1)	3 (15)
Appendectomy	4 (7)	1 (2.7)	3 (15)
UC disease extension
Proctitis		3 (8.1)
Left-sided		19 (51.4)
Extensive		15 (40.5)
CD disease location
Ileal (L1)			8 (40)
Colonic (L2)			4 (20)
Ileo-colonic (L3)			8 (40)
CD perianal involvement			8 (40)
CD disease behavior
Inflammatory disease (B1)			12 (60)
Stenosing (B2)			4 (20)
Penetrating (B3)			4 (20)
Extraintestinal manifestations	27 (47.4)	16 (43.2)	11 (55)
Erythema nodosum	1 (1.8)		1 (5)
Pyoderma gangrenous	1 (1.8)	1 (2.7)
Peripheral arthralgia	17 (29.8)	10 (27)	7 (35)
Peripheral arthritis	9 (15.8)	6 (16.2)	3 (15)
Back pain	11 (19.3)	5 (13.5)	6 (30)
Ankylosing spondylitis	4 (7)	1 (2.7)	3 (15)
Sacroiliitis	2 (3.5)	1 (2.7)	1 (5)
Aphthous ulcer	8 (14)	5 (13.5)	3 (15)
Current treatment	42 (73.7)	26 (70.3)	16 (80)
Mesalazine	24 (42.1)	21 (56.8)	3 (15)
Thiopurine	3 (5.3)	2 (5.4)	1 (5)
Biologics
Adalimumab	5 (8.8)	1 (2.7)	4 (20)
Infliximab	8 (14)	1 (2.7)	7 (35)
Vedolizumab	2 (3.5)	1 (2.7)	1 (2.7)
Prior major abdominal surgery
Resection	8 (14)		8 (40)
Total colectomy	2 (3.5)	2 (5.4)
CRP (mg/L)	8 (5-19.7)	6.14 (5-10.75)	17.1 (5.25-60)
HB (g/dL)	11.4 (10.03-12)	11.7 (10.1-12)	10.65 (9.68-12.6)
Albumin (g/dL)	4 (4-4.4)	4 (4-4.3)	4.15 (3.85-4.48)
Baseline partial Mayo score		6 (4-7.5)
Baseline Mayo endoscopic score		2 (2-3)
Baseline CDAI			330.5 (244.75-438.25)

BMI: Body mass index; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; CRP: C-reactive protein; HB: Hemoglobin; CDAI: Crohn’s disease activity index.